News and Events
AADE responds to ACCORD Trial Announcement
On Wednesday, February 6, 2008, The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes for Health announced that it has stopped the intensive blood sugar lowering treatment strategy used in its clinical trial of diabetes and cardiovascular disease.
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) study enrolled adults with type 2 diabetes who are at especially high risk for heart attack and stroke. Using intensive treatment strategies to lower A1C levels to less than 6 percent was shown to increase the risk of death compared to the less-intensive standard treatment. This result prompted NHLBI to stop the intensive blood glucose lowering treatment and continue the study with patients receiving standard treatment.
The ACCORD announcement spurred a number of responses from such organizations as the American Association of Clinical Endocrinologists and the American Diabetes Association.
AADE would like to caution the diabetes community against changing blood glucose monitoring treatment recommendations based solely on the findings of the ACCORD study. The data, as of now, is incomplete, and there are many factors that could have played a role in the increased morbidity rate of the patients in this trial. AADE looks forward to additional analysis of this study.
Read the NIH release on this issue.
Rob's test: http://www.diabeteseducator.org/event/web_091708